Form 4: Avidity Biosciences Chief Program Officer Exercises Options and Sells Shares Under Pre-Arranged Trading Plan

Kathleen P. Gallagher, Chief Program Officer at Avidity Biosciences, Inc., executed a pre-planned transaction on June 2, 2025, exercising stock options and subsequently selling 5,875 shares of common stock.

Summary

• Kathleen P. Gallagher, Chief Program Officer of Avidity Biosciences, Inc. (RNA), exercised 5,875 stock options on June 2, 2025, at an exercise price of $16.65 per share.
• Concurrently, Ms. Gallagher sold 5,875 shares of Avidity Biosciences common stock at a weighted-average price of $32.4822 per share.
• The sale price for the shares ranged from $31.10 to $33.22 per share.
• Following these transactions, Ms. Gallagher directly beneficially owns 50,554 shares of common stock and 22,596 stock options.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted by Ms. Gallagher on June 12, 2024.
• The exercised options were granted on July 18, 2022, and vest in equal monthly installments, becoming fully vested and exercisable on July 18, 2026.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can sometimes be viewed negatively, the fact that it was executed under a pre-arranged Rule 10b5-1 plan mitigates concerns about its implications for the company's immediate prospects. It represents a routine liquidity event for an executive.

Positives

• The exercise of options indicates that the stock price is above the exercise price, allowing the officer to realize value from their compensation.
• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and compliant sale rather than an immediate reaction to new information.

Negatives

• The sale of shares by a Chief Program Officer, even if pre-planned, could be perceived by some investors as a lack of confidence in the company's near-term stock performance.

Future Outlook

NA

Management Comments

• "This option exercise and sale was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024."
• "This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.10 to $33.22."
• "The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."
• "This option was granted on July 18, 2022 and vests in equal installments of 1/48 of the original number of shares subject to the option on each monthly anniversary of such grant date, until it is fully vested and exercisable on July 18, 2026."

Industry Context

This Form 4 filing details an insider transaction, which is a routine disclosure for publicly traded companies. It does not provide information on broader industry trends or competitive landscape within the biotechnology sector.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale of shares by a Chief Program Officer, even if pre-planned, might be interpreted by some shareholders as a signal, though the Rule 10b5-1 plan suggests it's a routine liquidity event rather than a reaction to new information.

Next Steps

• The Reporting Person undertakes to provide full information regarding the number of shares sold at each separate price within the stated range upon request.

Key Dates

Keywords

Avidity Biosciences, RNA, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Rule 10b5-1 Plan, Kathleen P. Gallagher, Chief Program Officer, Biotechnology, SEC Filing